Connective Capital Management Exits Position in Iradimed Corp (IRMD)

Iradimed Corp (IRMD) : Connective Capital Management has sold out all of its stake in Iradimed Corp during the most recent quarter, according to the disclosure filed by the company on Aug 9, 2016 with the SEC. The investment management company has sold out 24,053 shares of Iradimed Corp which is valued at $423,333.

Other Hedge Funds, Including , Awm Investment Company reduced its stake in IRMD by selling 22,657 shares or 12.48% in the most recent quarter. The Hedge Fund company now holds 158,830 shares of IRMD which is valued at $2,795,408. Iradimed Corp makes up approx 0.55% of Awm Investment Company’s portfolio.Oxford Asset Management boosted its stake in IRMD in the latest quarter, The investment management firm added 15,247 additional shares and now holds a total of 43,742 shares of Iradimed Corp which is valued at $755,862. Iradimed Corp makes up approx 0.03% of Oxford Asset Management’s portfolio. Mesirow Financial Investment Management – Equity Management added IRMD to its portfolio by purchasing 12,550 company shares during the most recent quarter which is valued at $216,864. Iradimed Corp makes up approx 0.01% of Mesirow Financial Investment Management – Equity Management’s portfolio. Gerstein Fisher sold out all of its stake in IRMD during the most recent quarter. The investment firm sold 40,459 shares of IRMD which is valued $699,132.Navellier Associates Inc reduced its stake in IRMD by selling 922 shares or 8.44% in the most recent quarter. The Hedge Fund company now holds 10,000 shares of IRMD which is valued at $177,000. Iradimed Corp makes up approx 0.03% of Navellier Associates Inc’s portfolio.

Iradimed Corp opened for trading at $18.15 and hit $18.16 on the upside on Wednesday, eventually ending the session at $17.33, with a gain of 0.29% or 0.05 points. The heightened volatility saw the trading volume jump to 1,81,878 shares. Company has a market cap of $185 M.

On the company’s financial health, Iradimed Corp reported $0.24 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $0.21. The company had revenue of $9.90 million for the quarter, compared to analysts expectations of $9.61 million. The company’s revenue was up 30.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.16 EPS.

IRADIMED CORPORATION (IRADIMED) develops manufactures markets and distributes Magnetic Resonance Imaging (MRI) compatible products and provides non-magnetic intravenous (IV) infusion pump systems. The Company’s electromechanical medical devices and pumps contain magnetic and electronic parts which generate radio frequency (RF) noise create interference and are dangerous to operate in the presence of the magnet which drives an MRI. The Company’s MRidium 3860+ MRI compatible IV infusion pump system consists of non-ferrous parts ceramic ultrasonic motors non-magnetic mobile stands and other special features to deliver anesthesia and other IV fluids during various MRI procedures. As of December 31 2014 the Company had approximately 2300 MRI compatible IV infusion pump systems installed globally. Each system consists of an MRidium MRI compatible IV infusion pump mobile stand and disposable IV tubing sets.

Leave a Reply

Iradimed Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Iradimed Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.